Date

2025-06-23

Protocol

Protocol changed

Item Changed

Exclusion criteria

Previous Version

1. Taking an ACE-I that cannot be switched to any of the following alternatives: • telmisartan 20 or 40mg, amlodipine 2.5 or 5mg, indapamide 1.25 or 2.5mg, or • an equivalent class (ARB, CCB or thiazide-like diuretic), or • a beta-blocker 2. Contraindication to any of the study medications, in the context of currently prescribed lowering medication 3. Unlikely/unable to complete the study procedures and/or follow-up 4. Females of child bearing age and capability, who are pregnant or breast-feeding, or those not Using adequate birth control

Next Version

1. Taking an ACE-I that cannot be switched to any of the following alternatives: • telmisartan 20 or 40mg, amlodipine 2.5 or 5mg, indapamide 1.25 or 2.5mg, or • an equivalent class (ARB, CCB or thiazide-like diuretic), or • a beta-blocker 2. Contraindication to any of the study medications, in the context of currently prescribed lowering medication 3. Unlikely/unable to complete the study procedures and/or follow-up 4. Females of child bearing age and capability, who are pregnant or breast-feeding, or those not Using adequate birth control 5. Significant hyperkalaemia and/or hyponatremia, in the opinion of the responsible physician 6. Estimated glomerular filtration rate (eGFR) 3x the upper limit of normal [ULN]) 7. Any other conditions that in the opinion of the responsible physician or investigator that renders the patient unsuitable for the study (e.g. severe disability [i.e. simplified modified Rankin Scale (smRS) of 4-5] or significant memory or behavioural disorder) 8. Exclusion criteria for MRI (as applies) • Any MRI contraindications (e.g. me06 December 2022tallic implants, claustrophobia, etc) or participant refusal